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Beta(2)-adrenergic receptors (adrenoceptors) are activated by the catecholamines norepinephrine and 
epinephrine. Adrenoceptors are found in different tissues, such as smooth muscle, skeletal muscle and 
myocardium. Stimulation of adrenoceptors is implicated in several physiological functions in the body, such 
as bronchodilation, increased perfusion and vasodilation. The latters, together with increased muscular mass 
and contraction speed, facilitate muscle’s motility and contraction. In the cardiovascular system, the activation 
of adrenoceptors increases heart muscle contraction, cardiac output and heart rate. Some studies also 
suggested a cardioprotective role of the stimulation of adrenoceptors. Beta(2)-adrenergic receptors agonists, 
principally divided in long-acting beta(2) agonists (LABAs) and short-acting beta(2) agonists (SABAs), are 
primarily used to treat asthma and other pulmonary disorders. Beta(2)-adrenergic receptors activation has 
been correlated with anabolic properties and muscular hypertrophy with the use of oral clenbuterol, as well 
as intravenous albuterol. Given these anabolic, lipolytic and performance-enhancing effects, LABAs are 
frequently abused by athletes. For this reason, most of these drugs are banned by the World Anti-Doping 
Agency, or admissible only with limitations. The aim of this narrative review is to report the results of some 
recent studies about the effects of beta(2)-adrenergic receptors activation on the cardiovascular system and 
on the skeletal muscle. 
Keywords: Beta(2)-adrenergic receptors; Beta(2)-agonist; Catecholamines; Cardiovascular system; Skeletal 
muscle; Doping. 
 
1 Corresponding author. Department of Public Health, University Federico II of Naples, Italy. 
E-mail: domiziano22@gmail.com 
Abstract submitted to: Winter Conferences of Sports Science. Costa Blanca Sports Science Events, 22-23 March 2021. 
Alicante, Spain. 
 JOURNAL OF HUMAN SPORT & EXERCISE ISSN 1988-5202. 
 © Faculty of Education. University of Alicante. 
 doi:10.14198/jhse.2021.16.Proc3.53 
Cite this article as: 
Romano, V., Cozzolino, D., Zinno, G., Palermi, S., & Tarantino, D. (2021). The effects of beta (2)-adrenergic 
receptors activation on the cardiovascular system and on the skeletal muscle: A narrative review. Journal of 
Human Sport and Exercise, 16(3proc), S1373-S1383. https://doi.org/10.14198/jhse.2021.16.Proc3.53 
Proceeding 
Romano, et al. / Beta (2)-adrenergic receptors activation                                                 JOURNAL OF HUMAN SPORT & EXERCISE 




Beta-2 (β2)-adrenergic receptor (ar) is a subtype of adrenergic receptors which binds several endogenous 
hormones such as the catecholamines norepinephrine and epinephrine, resulting in several types of 
responses. β2-ar is mainly expressed in the airways and in the vascular smooth muscle, but some studies 
also found its presence in the myocardium, although the β1-ar subtype is the most expressed in heart (Brodde 
et al., 2006). 
 
β2-ar selective agonists are derived from the chemical structure of adrenaline. They are traditionally used for 
the treatment of bronchospasm associated with asthma and the treatment of symptomatic patient with chronic 
obstructive pulmonary disease (COPD) to induce a bronchodilatation by relaxing airway smooth muscle 
(Cazzola et al., 1997). 
 
Stimulation of adrenoceptors is also implicated in muscle’s contraction and motility. This happens through a 
mechanism of increased perfusion and vasodilation of blood vessels to skeletal muscle, but also through a 
mechanism of increased mass and contraction speed (Rang et al., 2003). 
 
The skeletal muscle’s microvasculature response to β2-ar stimuli was recently found to be diminished with 
cardiac surgery (Ziegler et al., 2020). 
 
It has been widely accepted that activation of muscle β2-ars with the use of β2-ar agonists, principally divided 
in long-acting β2-agonists (LABAs) and short-acting β2-agonists (SABAs), leads to muscle hypertrophy and 
skeletal muscle repair in vivo (Chikazawa and Sato, 2018b; Jean-Baptiste et al., 2005; Sato et al., 2011). 
 
LABAs, such as clenbuterol, are frequently abused performance-enhancing drugs for their anabolic, lipolytic, 
and performance-enhancing effects (Davis et al., 2008). SABAs, such as albuterol, were not found to 
generate the same impacts on muscle mass if administered orally, suggesting that drugs with a short half-
life are not able to achieve these effects unless they are administered by intravenous route (Choo et al., 
1992; Kamalakkannan et al., 2008). Indeed, the use by athletes of β2-ar agonists such as clenbuterol is 
strictly prohibited, and it would be considered a doping violation (Chikazawa and Sato, 2018b), since these 
drugs are banned by the World Anti-Doping Agency, though some are permissible under a therapeutic use 
exemption (such as for asthma). 
 
Recent studies reported the correlation of a different expression of β2-ar in the myocardium and heart 
diseases, potentially allowing to detect new markers of myocardium infarction. Moreover, β2-ar can be a 
potential therapy target for several heart diseases (Li et al., 2019; Xia et al., 2017). In addition, β2-ars are 
also present on endothelial cells where they modulate vasodilation and angiogenesis (Chisholm et al., 2012; 
Guimarães and Moura, 2001). 
 
Several studies investigated the role of β2-ar agonists as pharmacologic agents aimed at reversing 
pathological conditions associated with skeletal muscle wasting such as sarcopenia and frailty (Kim et al., 
2018, 2020). Even in the case of severe muscle wasting, such as after a spinal cord injury, a role for systemic 
β2-ar-mediated mitochondrial biogenesis in improving skeletal muscle recovery was found (Scholpa et al., 
2019). 
 
In this review we will report the results of some recent studies about the effects of β2-ar activation on the 
cardiovascular system and on the skeletal muscle. 
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STRUCTURE AND PATHWAYS RELATED TO THE β2-ADRENERGIC RECEPTOR’S ACTIVATION 
 
The β2-ars are a subtype of β-adrenergic receptors, belonging to the superfamily G protein coupled receptors 
(GPCR). GPCRs have a conserved core of seven transmembrane α-helices that are connected by three 
extracellular and intracellular loops. Some of these receptors are known as potent inducers of hypertrophy 
(Berdeaux and Stewart, 2012), and there is evidence about the importance of the regulation of the activation 
of GPCRs for the maintenance of skeletal muscle function (Chikazawa and Sato, 2018b). They transduce a 
signal from the extracellular environment to the intracellular ones. The signal transduction starts with the 
binding of an endogenous hormone (epinephrine and norepinephrine for the adrenergic receptors) leading 
to a conformation change that activate the intramembrane protein G, an heterotrimer with three subunits: α, 
β, γ. The activation of G protein leads to a loss of affinity of GDP for GTP with the consequently dissociation 
of the heterotrimer Gα and Gβγ active subunits, mediating the intracellular signal transduction. Gα subunits 
are grouped in 4 subfamilies: Gαs, Gαi, Gαq and Gα12. These different subunits modulate the release of a 
second messenger in the cytoplasm. β-ars are mainly associated with G stimulating (Gs), leading to the 
activation of adenylate cyclase with the consequent increasing of cyclic adenosine monophosphate, cAMP, 
which activates cAMP dependent-kinases protein kinase A (PKA). PKA phosphorylates troponin I and Ca2+ 
channel, activating it, and finally inducing organism response (Freedman and Lefkowitz, 2004). 
 
Intracellular cAMP enhances cAMP-response element binding protein (CREB) phosphorylation and CREB 
target gene expression, which is assumed to be critical for myogenic differentiation and myofiber survival. 
Gαi-coupled receptors activate both the PI3K–AKT and mTOR signalling pathway, resulting in an increase 
in muscle protein synthesis (Minetti et al., 2011). The 3′-phosphoinositide–dependent kinase 1 (PDK1), a key 
component of PI3K signalling pathway, was found to regulate skeletal muscle mass under the static condition 
and that it contributes to mechanical load–induced muscle hypertrophy, at least in part by mediating signalling 
from β2-ar (Kuramoto et al., 2021). 
 
A common genetic variant in the β2-ar, the Arg16Gly genotype was found to have a significant effect on fat-
free mass, muscle strength and motor unit behaviour in recreationally trained men (Jenkins et al., 2018). 
These data might have important clinical and exercise-related implications. For example, β2-AR (rs1042713) 
genotype might influence the responsiveness of skeletal muscle to clinical or exercise-based interventions 
or β-ar agonist treatment (Jenkins et al., 2018). 
 
RELATIONSHIP BETWEEN LOCALIZATION AND FUNCTION OF β2-ADRENERGIC RECEPTORS IN 
THE CARDIOVASCULAR SYSTEM 
 
β2-ars are estimated to be the 25% of all adrenergic receptors in myocardium, while β1-ars are the most 
expressed adrenergic receptors in the heart (75%) (Brodde et al., 2006). β1-ars are the most expressed 
adrenergic receptor in the cardiomyocyte, while β2-ars are mainly expressed in cardiac fibroblasts, where 
they modulate collagen secretion and fibroblast autophagy, although the mechanism is still not totally 
understood (Bristow et al., 1986; Meszaros et al., 2000). 
 
New findings were available in the last two decades for β-ar signalling. In the classic linear model, β-ars were 
thought to primarily mediate cardiac functions such as inotropy, chronotropy, and lusitropy through the 
activation of stimulating Gs pathway, activating the adenylate cyclase which increases cAMP’s intracellular 
concentration (Guimarães and Moura, 2001; Xia et al., 2017). Increased cAMP’s concentration leads to the 
activation of PKA, which phosphorylates several downstream proteins like calcium ATPase enhancing 
intracellular calcium concentration with a consequent increase of heart contractions and blood flow rate 
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(Bernstein et al., 2011). The presence of both β1 and β2 adrenergic receptors in the heart generates a 
difference in the cAMP local concentration depending on the spatial localization of adrenergic receptors. β2-
ar was also found to be localized in caveolae, an invagination of plasma membrane enriched in cholesterol, 
glycophospholipids, so this could be associated to a cardioprotective effect of β2-ars (Agarwal et al., 2011; 
Bernstein et al., 2011; Head et al., 2005; Woo and Xiao, 2012; Xiang et al., 2002; Zhu et al., 2001). 
 
EFFECT OF β2- ADRENERGIC RECEPTOR’S ACTIVATION ON THE CARDIOVASCULAR SYSTEM 
 
Recent studies found that, unlike β1-ar, β2-ar can activate both Gs and Gi pathways, decreasing cAMP 
concentration, and activating another pathway inhibiting cardiomyocytes apoptosis with a cardioprotective 
effect (Santos and Spadari-Bratfisch, 2006). Another study underlined the cardioprotective effect of an 
overstimulation of β2-ars, regulating macrophage activation and decreasing the possibility to develop heart 
injuries (Noh et al., 2017). The role of extracellular matrix (ECM) has been shown to be pivotal in cardiac 
regeneration and repair after cardiac injury (Castaldo et al., 2013; Belviso et al., 2020a; Belviso et al., 2020b), 
and a recent study discovered that β2-ars are also involved in the maintenance of the cardiac matrix’s 
homeostasis, modulating collagen secretion and fibroblast autophagy, so that might contribute to prevent 
fibrosis due to pathological adrenergic stimulation (Aránguiz-Urroz et al., 2011). Another study underlined the 
cardioprotective effect of β2-ar stimulation, activating pro-survival kinases and reducing mitochondrial 
disfunction; in fact, β2-ar knock up enhances cardiotoxicity downregulating survival kinases and damaging 
the mitochondrial membrane (Fajardo et al., 2011). 
 
In contrast with the β2 cardioprotective effect, some studies revealed a relationship between heart failure and 
over-stimulation of β2-ar in subject with type-2 diabetes, since β2-ar antagonists were found to reduce heart 
complications in type-2 diabetes. These findings could contribute to discover a new therapeutic target in β2-
ar preventing and treating type-2 diabetes associated cardiac disfunction (Rybin et al., 2000; Spadari et al., 
2018; Wang et al., 2017; Wright et al., 2014). β2-ar was found to be involved in the modulation of vasodilation 
via Gαs/AC/PKA pathway trough the activation of the endothelial nitric oxide synthase. Furthermore, β2-ar 
stimulation was found to be related to the activation of the vascular endothelial growth factor and the basic 
fibroblast growth factor, both activating proangiogenic pathways (D’Angelo et al., 1997; Iaccarino et al., 2005; 
Storch and Hoeger, 2010). A recent study has revealed that β2-ar is overexpressed in infantile haemangioma, 
so it might be used as predictive marker and a preventive therapy target of vascular cancer (Chisholm et al., 
2012). 
 
EFFECT OF β2- ADRENERGIC RECEPTOR’S ACTIVATION ON THE MUSCULOSKELETAL SYSTEM 
 
Skeletal muscle mass is controlled by balancing protein synthesis and degradation (Chikazawa & Sato, 
2018a). Decreased protein synthesis and/or increased protein degradation for a prolonged period of time, 
which may be caused by inactivity, inadequate diet, reduced hormone levels or disease, contribute to a 
decrease in skeletal muscle mass and the onset of atrophy (Chikazawa & Sato, 2018a; Toledo et al., 2016). 
 
The hypertrophy and anti-atrophy effects of β2-ar-agonists can be explained by their actions on the balance 
between protein synthesis and protein degradation (Joassard et al., 2013). Previous studies indicate that 
chronic administration of β2-ar-agonists not only increases muscle protein synthesis, but also decreases 
muscle protein degradation (Busquets et al., 2004; Koopman et al., 2010; Navegantes et al., 2000, 2001, 
2004). 
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β2-ar agonist clenbuterol administration was found to improve skeletal muscle atrophy induced by hindlimb 
unweighting, denervation, and dexamethasone treatment through the activation of protein synthesis and 
inhibition of protein degradation by controlling lysosomal and proteasomal activity in animal models 
(Chikazawa and Sato, 2018a; Gonçalves et al., 2011; Pellegrino et al., 2004; Yimlamai et al., 2005). 
 
The preclinical data reported in a study by Koziczak-Holbro et al. (Koziczak-Holbro et al., 2019) showed that 
a novel 5-hydroxybenzothiazolone (5-HOB) derived b2-ar agonist is a strong, selective β2-ar agonist that is 
effective in promoting skeletal muscle growth, displaying tissue selectivity and reduced cardiovascular 
effects, compared with the well-described formoterol. Hence, their results suggested that 5-HOB may provide 
a new valuable treatment option for muscle atrophy conditions (Koziczak-Holbro et al., 2019). 
 
Therefore, β2-ar agonists clearly have the potential to augment skeletal muscle mass and function (Jenkins 
et al., 2018). Kamalakkannan et al. (Kamalakkannan et al., 2008) observed a significant increase in lean 
mass and maximal strength after clenbuterol administration in chronic heart failure patients. Jessen et al. 
(Jessen et al., 2018) observed a 1.03 kg increase in lean body mass after only four weeks of daily inhaled 
terbutaline compared with placebo administration in healthy young men. Le Panse et al. (Le Panse et al., 
2005) observed important increases in peak power during maximal cycling exercise after three weeks of 
salbutamol ingestion in trained and untrained males. 
 
Hostrup et al. (Hostrup et al., 2015) observed a significant 1.95 kg increase in lean body mass, in addition to 
increased cross-sectional area of type I and type II fibres of the vastus lateralis, and an increase in maximal 
strength and in peak power during maximal cycling exercise after four weeks of twice daily oral terbutaline 
versus placebo administration in trained, healthy young men. 
 
Kim at al. (Kim et al., 2018) found out that the increase in skeletal muscle fibre size with chronic clenbuterol-
induced β2-ar stimulation was β-arrestin 1-dependent, indicating that β-arrestin 1 is a critical signalling 
molecule regulating skeletal muscle growth and function downstream of the β2-ar. 
 
The role of β-arrestin 1 was also studied with the use of carvedilol, a β-ar antagonist, widely used for the 
treatment of chronic systolic heart failure and hypertension. In a murine model, Kim et al. (Kim et al., 2020) 
showed that chronic treatment with carvedilol enhanced contractile force in skeletal muscle, and this process 
was mediated by β-arrestin 1. Carvedilol enhanced skeletal muscle contractility despite a lack of effect on 
skeletal muscle hypertrophy. So, these findings suggested a potential unique clinical role of carvedilol to 
stimulate skeletal muscle contractility while avoiding the adverse effects with β-ar agonists. 
 
A couple of recent studies by Chikazawa and Sato (Chikazawa and Sato, 2018a, 2018b) showed that it is 
also possible to increase muscle β2-ar expression by dietary improvement, so this was thought to be a 
promising strategy for the maintenance of healthy skeletal muscle and for achieving muscle hypertrophy. 
Resveratrol (a polyphenolic compound) and genistein (an isoflavone found in soybean) were shown to 
increase the β2-ar mRNA levels in skeletal muscle cells (Chikazawa and Sato, 2018b). Gramine (a natural 
indole alkaloid) and hordenine (an alkaloid of the phenethylamine class), if administered by intramuscular 
route, were shown to increase the expression of hypertrophic genes in mice quadriceps, which was 
suggested to have been mediated, at least in part, by the β2-ar activation, giving new possible therapeutic 
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DISCUSSION AND CONCLUSIONS 
 
Collectively, there is a strong evidence supporting the importance of the β2-ar in the heart. Although β1-ar is 
the main modulator of the cardiac muscle’s contraction, this mechanism is also involved in several heart 
disfunctions (Noh et al., 2017). β2-ar was found to potentially enhance heart contractions without the negative 
effects seen through the overstimulation of β1-ar (Bernstein et al., 2011). 
 
The data reviewed here suggested that β2-ar’s activation has some beneficial effects on the heart, such as 
a cardioprotective effect due to the alternative activation of β2-ar/Gi/PI3K pathway that leads to a decrease 
in cardiomyocyte apoptosis (Li et al., 2019). Therefore, β2-ars represent a potential therapeutic target for the 
treatment of cardiac diseases and vascular tumours (Aránguiz-Urroz et al., 2011; Rybin et al., 2000; Storch 
and Hoeger, 2010). However, further studies are needed to understand the intracellular signalling regulated 
by β2-ars, so then its use could be extended to treat a variety of cardiovascular diseases. 
 
Maintaining skeletal muscle mass and function is vital for ameliorating the quality of life of elderly people 
(Chikazawa and Sato, 2018b). The data from the reported studies suggested that β2-ar agonists could be 
used as pharmacologic agents to prevent skeletal muscle wasting, increasing muscle mass and preventing 
atrophy (Chikazawa and Sato, 2018a). 
 
Anyway, since most of those studies were performed in vitro, further studies are needed before they could 




Agarwal, S. R., MacDougall, D. A., Tyser, R., Pugh, S. D., Calaghan, S. C., & Harvey, R. D. (2011). 
Effects of cholesterol depletion on compartmentalized cAMP responses in adult cardiac myocytes. 
Journal of Molecular and Cellular Cardiology, 50(3), 500-509. 
https://doi.org/10.1016/j.yjmcc.2010.11.015 
Aránguiz-Urroz, P., Canales, J., Copaja, M., Troncoso, R., Vicencio, J. M., Carrillo, C., Lara, H., 
Lavandero, S., & Díaz-Araya, G. (2011). Beta2-adrenergic receptor regulates cardiac fibroblast 
autophagy and collagen degradation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of 
Disease, 1812(1), 23-31. https://doi.org/10.1016/j.bbadis.2010.07.003 
Belviso, I., Angelini, F., Di Meglio, F., Picchio, V., Sacco, AM., Nocella, C., Romano, V., Nurzynska, D., 
Frati, G., Maiello, C., Messina, E., Montagnani, S., Pagano, F., Castaldo, C., Chimenti, I. (2020a). 
The Microenvironment of Decellularized Extracellular Matrix from Heart Failure Myocardium Alters 
the Balance between Angiogenic and Fibrotic Signals from Stromal Primitive Cells. Int J Mol Sci, 
21(21):7903. https://doi.org/10.3390/ijms21217903 
Belviso, I., Romano, V., Sacco, AM., Ricci, G., Massai, D., Cammarota, M., Catizone, A., Schiraldi, C., 
Nurzynska, D., Terzini, M., Aldieri, A., Serino, G., Schonauer, F., Sirico, F., D'Andrea, F., 
Montagnani, S., Di Meglio, F., Castaldo, C. (2020b). Decellularized Human Dermal Matrix as a 
Biological Scaffold for Cardiac Repair and Regeneration. Front Bioeng Biotechnol, 20;8:229. 
http://doi.org/10.3389/fbioe.2020.00229 
Berdeaux, R., & Stewart, R. (2012). cAMP signaling in skeletal muscle adaptation: Hypertrophy, 
metabolism, and regeneration. American Journal of Physiology. Endocrinology and Metabolism, 
303(1), E1-17. https://doi.org/10.1152/ajpendo.00555.2011 
Romano, et al. / Beta (2)-adrenergic receptors activation                                                 JOURNAL OF HUMAN SPORT & EXERCISE 
                     VOLUME 16 | Proc3 | 2021 |   S1379 
 
Bernstein, D., Fajardo, G., & Zhao, M. (2011). The role of β-adrenergic receptors in heart failure: 
differential regulation of cardiotoxicity and cardioprotection. Progress in Pediatric Cardiology, 31(1), 
35-38. https://doi.org/10.1016/j.ppedcard.2010.11.007 
Bristow, M. R., Ginsburg, R., Umans, V., Fowler, M., Minobe, W., Rasmussen, R., Zera, P., Menlove, R., 
Shah, P., & Jamieson, S. (1986). Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing 
and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction 
and selective beta 1-receptor down-regulation in heart failure. Circulation Research, 59(3), 297-309. 
https://doi.org/10.1161/01.res.59.3.297 
Brodde, O.-E., Bruck, H., & Leineweber, K. (2006). Cardiac adrenoceptors: Physiological and 
pathophysiological relevance. Journal of Pharmacological Sciences, 100(5), 323-337. 
https://doi.org/10.1254/jphs.crj06001x 
Busquets, S., Figueras, M. T., Fuster, G., Almendro, V., Moore-Carrasco, R., Ametller, E., Argilés, J. M., 
& López-Soriano, F. J. (2004). Anticachectic effects of formoterol: A drug for potential treatment of 
muscle wasting. Cancer Research, 64(18), 6725-6731. https://doi.org/10.1158/0008-5472.CAN-04-
0425 
Castaldo, C., Di Meglio, F., Miraglia, R., Sacco, AM., Romano, V., Bancone, C., Della Corte, A., 
Montagnani, S., Nurzynska, D. (2013). Cardiac fibroblast-derived extracellular matrix (biomatrix) as 
a model for the studies of cardiac primitive cell biological properties in normal and pathological adult 
human heart. Biomed Res Int, 2013:352370. http://doi.org/10.1155/2013/352370 
Cazzola, M., Spina, D., & Matera, M. G. (1997). The use of bronchodilators in stable chronic obstructive 
pulmonary disease. Pulmonary Pharmacology & Therapeutics, 10(3), 129-144. 
https://doi.org/10.1006/pupt.1997.0087 
Chikazawa, M., & Sato, R. (2018a). Identification of Functional Food Factors as β2-Adrenergic Receptor 
Agonists and Their Potential Roles in Skeletal Muscle. Journal of Nutritional Science and 
Vitaminology, 64(1), 68-74. https://doi.org/10.3177/jnsv.64.68 
Chikazawa, M., & Sato, R. (2018b). Identification of a Novel Function of Resveratrol and Genistein as a 
Regulator of β2 -Adrenergic Receptor Expression in Skeletal Muscle Cells and Characterization of 
Promoter Elements Required for Promoter Activation. Molecular Nutrition & Food Research, 62(22), 
e1800530. https://doi.org/10.1002/mnfr.201800530 
Chisholm, K. M., Chang, K. W., Truong, M. T., Kwok, S., West, R. B., & Heerema-McKenney, A. E. 
(2012). β-Adrenergic receptor expression in vascular tumors. Modern Pathology: An Official Journal 
of the United States and Canadian Academy of Pathology, Inc, 25(11), 1446-1451. 
https://doi.org/10.1038/modpathol.2012.108 
Choo, J. J., Horan, M. A., Little, R. A., & Rothwell, N. J. (1992). Anabolic effects of clenbuterol on skeletal 
muscle are mediated by beta 2-adrenoceptor activation. The American Journal of Physiology, 263(1 
Pt 1), E50-56. https://doi.org/10.1152/ajpendo.1992.263.1.E50 
D'Angelo, G., Lee, H., & Weiner, R. I. (1997). CAMP-dependent protein kinase inhibits the mitogenic 
action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells 
by blocking Raf activation. Journal of Cellular Biochemistry, 67(3), 353-366. 
https://doi.org/10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.0.CO;2-V 
Davis, E., Loiacono, R., & Summers, R. J. (2008). The rush to adrenaline: Drugs in sport acting on the 
β-adrenergic system. British Journal of Pharmacology, 154(3), 584-597. 
https://doi.org/10.1038/bjp.2008.164 
Fajardo, G., Zhao, M., Berry, G., Wong, L.-J., Mochly-Rosen, D., & Bernstein, D. (2011). Β2-adrenergic 
receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways. Journal 
of Molecular and Cellular Cardiology, 51(5), 781-789. https://doi.org/10.1016/j.yjmcc.2011.06.019 
Romano, et al. / Beta (2)-adrenergic receptors activation                                                 JOURNAL OF HUMAN SPORT & EXERCISE 
S1380 | 2021 | Proc2 | VOLUME 16                                                                                 © 2021 University of Alicante 
 
Freedman, N. J., & Lefkowitz, R. J. (2004). Anti-β1-adrenergic receptor antibodies and heart failure: 
Causation, not just correlation. Journal of Clinical Investigation, 113(10), 1379-1382. 
https://doi.org/10.1172/JCI200421748 
Gonçalves, D. A. P., Silveira, W. A., Lira, E. C., Graça, F. A., Paula-Gomes, S., Zanon, N. M., Kettelhut, 
I. C., & Navegantes, L. C. C. (2011). Clenbuterol suppresses proteasomal and lysosomal proteolysis 
and atrophy-related genes in denervated rat soleus muscles independently of Akt. American Journal 
of Physiology-Endocrinology and Metabolism, 302(1), E123-E133. 
https://doi.org/10.1152/ajpendo.00188.2011 
Guimarães, S., & Moura, D. (2001). Vascular adrenoceptors: An update. Pharmacological Reviews, 
53(2), 319-356. 
Head, B. P., Patel, H. H., Roth, D. M., Lai, N. C., Niesman, I. R., Farquhar, M. G., & Insel, P. A. (2005). 
G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular 
caveolin-3-associated microdomains in adult cardiac myocytes. The Journal of Biological Chemistry, 
280(35), 31036-31044. https://doi.org/10.1074/jbc.M502540200 
Hostrup, M., Kalsen, A., Onslev, J., Jessen, S., Haase, C., Habib, S., Ørtenblad, N., Backer, V., & 
Bangsbo, J. (2015). Mechanisms underlying enhancements in muscle force and power output during 
maximal cycle ergometer exercise induced by chronic β2-adrenergic stimulation in men. Journal of 
Applied Physiology (Bethesda, Md.: 1985), 119(5), 475-486. 
https://doi.org/10.1152/japplphysiol.00319.2015 
Iaccarino, G., Ciccarelli, M., Sorriento, D., Galasso, G., Campanile, A., Santulli, G., Cipolletta, E., Cerullo, 
V., Cimini, V., Altobelli, G. G., Piscione, F., Priante, O., Pastore, L., Chiariello, M., Salvatore, F., 
Koch, W. J., & Trimarco, B. (2005). Ischemic neoangiogenesis enhanced by beta2-adrenergic 
receptor overexpression: A novel role for the endothelial adrenergic system. Circulation Research, 
97(11), 1182-1189. https://doi.org/10.1161/01.RES.0000191541.06788.bb 
Jean-Baptiste, G., Yang, Z., Khoury, C., Gaudio, S., & Greenwood, M. T. (2005). Peptide and non-peptide 
G-protein coupled receptors (GPCRs) in skeletal muscle. Peptides, 26(8), 1528-1536. 
https://doi.org/10.1016/j.peptides.2005.03.011 
Jenkins, N. D. M., Colquhoun, R. J., Tomko, P. M., Gradnigo, T., Magrini, M. A., Muddle, T. W. D., 
Fleming, S., Ferrell, M., & El-Sohemy, A. (2018). Genetic variant in the β2 -adrenergic receptor 
(Arg16Gly) influences fat-free mass, muscle strength and motor unit behaviour in young men. 
Experimental Physiology, 103(12), 1645-1655. https://doi.org/10.1113/EP087145 
Jessen, S., Onslev, J., Lemminger, A., Backer, V., Bangsbo, J., & Hostrup, M. (2018). Hypertrophic effect 
of inhaled beta2 -agonist with and without concurrent exercise training: A randomized controlled trial. 
Scandinavian Journal of Medicine & Science in Sports, 28(10), 2114-2122. 
https://doi.org/10.1111/sms.13221 
Joassard, O. R., Amirouche, A., Gallot, Y. S., Desgeorges, M. M., Castells, J., Durieux, A.-C., Berthon, 
P., & Freyssenet, D. G. (2013). Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-
lysosome pathways in response to formoterol administration in rat skeletal muscle. The International 
Journal of Biochemistry & Cell Biology, 45(11), 2444-2455. 
https://doi.org/10.1016/j.biocel.2013.07.019 
Kamalakkannan, G., Petrilli, C. M., George, I., LaManca, J., McLaughlin, B. T., Shane, E., Mancini, D. 
M., & Maybaum, S. (2008). Clenbuterol increases lean muscle mass but not endurance in patients 
with chronic heart failure. The Journal of Heart and Lung Transplantation: The Official Publication of 
the International Society for Heart Transplantation, 27(4), 457-461. 
https://doi.org/10.1016/j.healun.2008.01.013 
Kim, J., Grotegut, C. A., Wisler, J. W., Li, T., Mao, L., Chen, M., Chen, W., Rosenberg, P. B., Rockman, 
H. A., & Lefkowitz, R. J. (2018). β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal 
Romano, et al. / Beta (2)-adrenergic receptors activation                                                 JOURNAL OF HUMAN SPORT & EXERCISE 
                     VOLUME 16 | Proc3 | 2021 |   S1381 
 
muscle hypertrophy and contractility. Skeletal Muscle, 8. https://doi.org/10.1186/s13395-018-0184-
8 
Kim, J., Grotegut, C. A., Wisler, J. W., Mao, L., Rosenberg, P. B., Rockman, H. A., & Lefkowitz, R. J. 
(2020). The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle 
contractility. Proceedings of the National Academy of Sciences, 117(22), 12435-12443. 
https://doi.org/10.1073/pnas.1920310117 
Koopman, R., Gehrig, S. M., Léger, B., Trieu, J., Walrand, S., Murphy, K. T., & Lynch, G. S. (2010). 
Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and 
breakdown during chronic {beta}-adrenoceptor stimulation in mice. The Journal of Physiology, 588(Pt 
23), 4811-4823. https://doi.org/10.1113/jphysiol.2010.196725 
Koziczak-Holbro, M., Rigel, D. F., Dumotier, B., Sykes, D. A., Tsao, J., Nguyen, N.-H., Bösch, J., 
Jourdain, M., Flotte, L., Adachi, Y., Kiffe, M., Azria, M., Fairhurst, R. A., Charlton, S. J., Richardson, 
B. P., Lach-Trifilieff, E., Glass, D. J., Ullrich, T., & Hatakeyama, S. (2019). Pharmacological 
Characterization of a Novel 5-Hydroxybenzothiazolone-Derived β2-Adrenoceptor Agonist with 
Functional Selectivity for Anabolic Effects on Skeletal Muscle Resulting in a Wider Cardiovascular 
Safety Window in Preclinical Studies. The Journal of Pharmacology and Experimental Therapeutics, 
369(2), 188-199. https://doi.org/10.1124/jpet.118.255307 
Kuramoto, N., Nomura, K., Kohno, D., Kitamura, T., Karsenty, G., Hosooka, T., & Ogawa, W. (2021). 
Role of PDK1 in skeletal muscle hypertrophy induced by mechanical load. Scientific Reports, 11(1), 
3447. https://doi.org/10.1038/s41598-021-83098-z 
Le Panse, B., Collomp, K., Portier, H., Lecoq, A.-M., Jaffre, C., Beaupied, H., Richard, O., Benhamou, 
L., De Ceaurriz, J., & Courteix, D. (2005). Effects of short-term salbutamol ingestion during a Wingate 
test. International Journal of Sports Medicine, 26(7), 518-523. https://doi.org/10.1055/s-2004-821224 
Li, Y., Yuan, H., Sun, L., Zhou, Q., Yang, F., Yang, Z., & Liu, D. (2019). β2-Adrenergic Receptor Gene 
Polymorphisms Are Associated with Cardiovascular Events But not All-Cause Mortality in Coronary 
Artery Disease Patients: A Meta-Analysis of Prospective Studies. Genetic Testing and Molecular 
Biomarkers, 23(2), 124-137. https://doi.org/10.1089/gtmb.2018.0153 
Meszaros, J. G., Gonzalez, A. M., Endo-Mochizuki, Y., Villegas, S., Villarreal, F., & Brunton, L. L. (2000). 
Identification of G protein-coupled signaling pathways in cardiac fibroblasts: Cross talk between G(q) 
and G(s). American Journal of Physiology. Cell Physiology, 278(1), C154-162. 
https://doi.org/10.1152/ajpcell.2000.278.1.C154 
Minetti, G. C., Feige, J. N., Rosenstiel, A., Bombard, F., Meier, V., Werner, A., Bassilana, F., Sailer, A. 
W., Kahle, P., Lambert, C., Glass, D. J., & Fornaro, M. (2011). Gαi2 Signaling Promotes Skeletal 
Muscle Hypertrophy, Myoblast Differentiation, and Muscle Regeneration. Science Signaling, 4(201), 
ra80-ra80. https://doi.org/10.1126/scisignal.2002038 
Navegantes, L. C., Resano, N. M. Z., Baviera, A. M., Migliorini, R. H., & Kettelhut, I. C. (2004). Effect of 
sympathetic denervation on the rate of protein synthesis in rat skeletal muscle. American Journal of 
Physiology. Endocrinology and Metabolism, 286(4), E642-647. 
https://doi.org/10.1152/ajpendo.00371.2003 
Navegantes, L. C., Resano, N. M., Migliorini, R. H., & Kettelhut, I. C. (2000). Role of adrenoceptors and 
cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle. American Journal 
of Physiology. Endocrinology and Metabolism, 279(3), E663-668. 
https://doi.org/10.1152/ajpendo.2000.279.3.E663 
Navegantes, L. C., Resano, N. M., Migliorini, R. H., & Kettelhut IC, null. (2001). Catecholamines inhibit 
Ca(2+)-dependent proteolysis in rat skeletal muscle through beta(2)-adrenoceptors and cAMP. 
American Journal of Physiology. Endocrinology and Metabolism, 281(3), E449-454. 
https://doi.org/10.1152/ajpendo.2001.281.3.E449 
Romano, et al. / Beta (2)-adrenergic receptors activation                                                 JOURNAL OF HUMAN SPORT & EXERCISE 
S1382 | 2021 | Proc2 | VOLUME 16                                                                                 © 2021 University of Alicante 
 
Noh, H., Yu, M. R., Kim, H. J., Lee, J. H., Park, B.-W., Wu, I.-H., Matsumoto, M., & King, G. L. (2017). 
Beta 2-adrenergic receptor agonists are novel regulators of macrophage activation in diabetic renal 
and cardiovascular complications. Kidney International, 92(1), 101-113. 
https://doi.org/10.1016/j.kint.2017.02.013 
Pellegrino, M. A., D'Antona, G., Bortolotto, S., Boschi, F., Pastoris, O., Bottinelli, R., Polla, B., & Reggiani, 
C. (2004). Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in 
mice. Experimental Physiology, 89(1), 89-100. https://doi.org/10.1113/expphysiol.2003.002609 
Rang, H. P., Dale, M. M., Ritter, J. M., & Moore, P. (2003). Pharmacology. Churchill Livingstone. 
Rybin, V. O., Xu, X., Lisanti, M. P., & Steinberg, S. F. (2000). Differential targeting of beta -adrenergic 
receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally 
regulate the cAMP signaling pathway. The Journal of Biological Chemistry, 275(52), 41447-41457. 
https://doi.org/10.1074/jbc.M006951200 
Santos, I. N., & Spadari-Bratfisch, R. C. (2006). Stress and cardiac beta adrenoceptors. Stress 
(Amsterdam, Netherlands), 9(2), 69-84. https://doi.org/10.1080/10253890600771858 
Sato, S., Shirato, K., Tachiyashiki, K., & Imaizumi, K. (2011). Muscle Plasticity and β2-Adrenergic 
Receptors: Adaptive Responses of β2-Adrenergic Receptor Expression to Muscle Hypertrophy and 
Atrophy. Journal of Biomedicine and Biotechnology, 2011. https://doi.org/10.1155/2011/729598 
Scholpa, N. E., Simmons, E. C., Tilley, D. G., & Schnellmann, R. G. (2019). Β2-adrenergic receptor-
mediated mitochondrial biogenesis improves skeletal muscle recovery following spinal cord injury. 
Experimental Neurology, 322, 113064. https://doi.org/10.1016/j.expneurol.2019.113064 
Spadari, R. C., Cavadas, C., de Carvalho, A. E. T. S., Ortolani, D., de Moura, A. L., & Vassalo, P. F. 
(2018). Role of Beta-adrenergic Receptors and Sirtuin Signaling in the Heart During Aging, Heart 
Failure, and Adaptation to Stress. Cellular and Molecular Neurobiology, 38(1), 109-120. 
https://doi.org/10.1007/s10571-017-0557-2 
Storch, C. H., & Hoeger, P. H. (2010). Propranolol for infantile haemangiomas: Insights into the molecular 
mechanisms of action. The British Journal of Dermatology, 163(2), 269-274. 
https://doi.org/10.1111/j.1365-2133.2010.09848.x 
Toledo, M., Busquets, S., Penna, F., Zhou, X., Marmonti, E., Betancourt, A., Massa, D., López-Soriano, 
F. J., Han, H. Q., & Argilés, J. M. (2016). Complete reversal of muscle wasting in experimental cancer 
cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist. International Journal 
of Cancer, 138(8), 2021-2029. https://doi.org/10.1002/ijc.29930 
Wang, Q., Liu, Y., Fu, Q., Xu, B., Zhang, Y., Kim, S., Tan, R., Barbagallo, F., West, T., Anderson, E., 
Wei, W., Abel, E. D., & Xiang, Y. K. (2017). Inhibiting Insulin-Mediated β2-Adrenergic Receptor 
Activation Prevents Diabetes-Associated Cardiac Dysfunction. Circulation, 135(1), 73-88. 
https://doi.org/10.1161/CIRCULATIONAHA.116.022281 
Woo, A. Y. H., & Xiao, R. (2012). β-Adrenergic receptor subtype signaling in heart: From bench to 
bedside. Acta Pharmacologica Sinica, 33(3), 335-341. https://doi.org/10.1038/aps.2011.201 
Wright, P. T., Nikolaev, V. O., O'Hara, T., Diakonov, I., Bhargava, A., Tokar, S., Schobesberger, S., 
Shevchuk, A. I., Sikkel, M. B., Wilkinson, R., Trayanova, N. A., Lyon, A. R., Harding, S. E., & Gorelik, 
J. (2014). Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-
mediated cAMP signaling. Journal of Molecular and Cellular Cardiology, 67, 38-48. 
https://doi.org/10.1016/j.yjmcc.2013.12.003 
Xia, K., Ding, R., Zhang, Z., Li, W., Shang, X., Yang, X., Wang, L., & Zhang, Q. (2017). The association 
of eight potentially functional polymorphisms in five adrenergic receptor-encoding genes with 
myocardial infarction risk in Han Chinese. Gene, 624, 43-49. 
https://doi.org/10.1016/j.gene.2017.04.045 
Romano, et al. / Beta (2)-adrenergic receptors activation                                                 JOURNAL OF HUMAN SPORT & EXERCISE 
                     VOLUME 16 | Proc3 | 2021 |   S1383 
 
Xiang, Y., Rybin, V. O., Steinberg, S. F., & Kobilka, B. (2002). Caveolar localization dictates physiologic 
signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. The Journal of Biological Chemistry, 
277(37), 34280-34286. https://doi.org/10.1074/jbc.M201644200 
Yimlamai, T., Dodd, S. L., Borst, S. E., & Park, S. (2005). Clenbuterol induces muscle-specific attenuation 
of atrophy through effects on the ubiquitin-proteasome pathway. Journal of Applied Physiology 
(Bethesda, Md.: 1985), 99(1), 71-80. https://doi.org/10.1152/japplphysiol.00448.2004 
Zhu, W. Z., Zheng, M., Koch, W. J., Lefkowitz, R. J., Kobilka, B. K., & Xiao, R. P. (2001). Dual modulation 
of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. 
Proceedings of the National Academy of Sciences of the United States of America, 98(4), 1607-
1612. https://doi.org/10.1073/pnas.98.4.1607 
Ziegler, O., Anderson, K., Liu, Y., Ehsan, A., Fingleton, J., Sodha, N., Feng, J., & Sellke, F. W. (2020). 
Skeletal muscle microvasculature response to β-adrenergic stimuli is diminished with cardiac 
































This work is licensed under a Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). 
